Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...

or on the link below. Prostate-specific antigen (PSA) is both a blessing and a curse for prostate cancer. It is a blessing because it makes prostate cancer one of the few cancers with a reliable serum ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Compared to White men, Black men have a higher risk of developing prostate cancer. Additionally, Black men have a greater risk than White men of prostate cancer mortality. Asian men have a lower risk ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...